Citius Pharmaceuticals Stock In The News
| CTXR Stock | USD 1.52 0.03 1.94% |
Our overall analysis of Citius Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Citius Pharmaceuticals. The specific impact of Citius Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Citius Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Citius Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Citius Pharmaceuticals Backtesting and Citius Pharmaceuticals Hype Analysis. To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Citius and other traded companies coverage with news coverage. We help investors stay connected with Citius headlines for the 23rd of March to make an informed investment decision based on correlating the impacts of news items on Citius Stock performance. Please note that trading solely based on the Citius Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Citius |
Citius Pharmaceuticals Today Top News and Investor Outlook
Citius Pharmaceuticals Past News Timeline
Citius Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Citius earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Citius Pharmaceuticals that are available to investors today. That information is available publicly through Citius media outlets and privately through word of mouth or via Citius internal channels. However, regardless of the origin, that massive amount of Citius data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Citius Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Citius Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Citius Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Citius Pharmaceuticals alpha.
Citius Largest EPS Surprises
Earnings surprises can significantly impact Citius Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-12 | 2024-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2024-05-14 | 2024-03-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2023-08-14 | 2023-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2022-12-22 | 2022-09-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2022-08-11 | 2022-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2020-08-14 | 2020-06-30 | -0.1 | -0.11 | -0.01 | 10 |
Citius Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Citius Pharmaceuticals Stock. Current markets are strongly bearish. About 79% of major world exchanges and indexes are down. See today's market update for more information.
19th of March 2025
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formul... at gurufocus.com
19th of March 2025
BioLineRx Downgraded by StockNews.com to Sell at thelincolnianonline.com
18th of March 2025
Acquisition by Michael Rowe of 4890 shares of Eyenovia at 1.36 subject to Rule 16b-3 at MacroaxisInsider
14th of March 2025
Eyenovia Inc expected to post a loss of 7.20 a share - Earnings Preview - TradingView at news.google.com
14th of March 2025
Seres Therapeutics, Inc. Are Analysts Optimistic at finance.yahoo.com
12th of March 2025
Acumen Pharmaceuticals to Present During International Conference on Alzheimers and Parkin... at finance.yahoo.com
12th of March 2025
New Fortress Energy price target lowered by 3 at Deutsche Bank, heres why NFE at thefly.com
12th of March 2025
Insider Buying David Mott Acquires Shares of Ardelyx Inc - GuruFocus.com at news.google.com
11th of March 2025
Terns Pharmaceuticals stock hits 52-week low at 3.27 - Investing.com at news.google.com
7th of March 2025
Acquisition by Wyzga Michael S of 25050 shares of Mereo BioPharma at 3.99 subject to Rule ... at MacroaxisInsider
7th of March 2025
Inozyme Pharma Inc expected to post a loss of 41 cents a share - Earnings Preview - Tradin... at news.google.com
7th of March 2025
Q4 2024 Lexicon Pharmaceuticals Inc Earnings Call Transcript at gurufocus.com
7th of March 2025
Seres Therapeutics Rating Increased to Hold at StockNews.com at thelincolnianonline.com
7th of March 2025
Top Growth Companies With Insider Stakes For March 2025 at simplywall.st
6th of March 2025
Make It A Trend Part 1 Valve Releases Team Fortress 2 Source Code at techdirt.com
6th of March 2025
JPMorgan Chase Co. Lowers Day One Biopharmaceuticals Price Target to 34.00 - Defense World at news.google.com
5th of March 2025
Cantor Fitzgerald Upgrades Ardelyx to Strong-Buy at thelincolnianonline.com
4th of March 2025
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual ... at gurufocus.com
4th of March 2025
Neumora bids farewell to RD head Biohavens one step forward, one step back data at finance.yahoo.com
4th of March 2025
ImmunityBio Full Year 2024 Earnings EPS Beats Expectations, Revenues Lag at finance.yahoo.com
3rd of March 2025
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cel... at gurufocus.com
28th of February 2025
What is Wedbushs Forecast for DAWN Q1 Earnings at thelincolnianonline.com
28th of February 2025
ImmunityBio Inc Under Investigation for Alleged Misleading Statements at gurufocus.com
25th of February 2025
Acquisition by Peters Malte of 52000 shares of Hookipa Pharma at 1.01 subject to Rule 16b-... at MacroaxisInsider
25th of February 2025
DAWN chiede alla Corte penale internazionale di indagare sullamministrazione Biden per fav... at businesswire.com
21st of February 2025
Biotech Alert Searches spiking for these stocks today - TipRanks at news.google.com
20th of February 2025
BioMarin Q4 Earnings Sales Top Estimates, Stock Up on Upbeat 25 View at zacks.com
20th of February 2025
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business ... at gurufocus.com
19th of February 2025
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement f at gurufocus.com
18th of February 2025
Revolutionizing Connectivity Fortress Solutions, Ataya, and Moso Networks Partner for Pre-... at finance.yahoo.com
18th of February 2025
Insider Trading at MacroaxisInsider
18th of February 2025
Disposition of 4416 shares by Von Moltke Lisa of Seres Therapeutics at 0.8105 subject to R... at MacroaxisInsider
6th of February 2025
One year after drug approval, X4 Pharmaceuticals cuts staff at bizjournals.com
6th of February 2025
BlackRock, Inc. Increases Stake in Terns Pharmaceuticals Inc at gurufocus.com
5th of February 2025
Acumen Pharmaceuticals, Inc. Short Interest Update - MarketBeat at news.google.com
31st of January 2025
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance at news.google.com
30th of January 2025
Lexicon Pharmaceuticals Given Hold Rating at Needham Company LLC - MarketBeat at news.google.com
29th of January 2025
Top 9 Biotech Stocks Poised for Momentum Gains - TheStreet at news.google.com
28th of January 2025
Eyenovia Announces 1-for-80 Reverse Stock Split at gurufocus.com
27th of January 2025
Amendment SEC Form 10-KA filed by Citius Pharmaceuticals Inc. - Quantisnow at news.google.com
27th of January 2025
Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. Stock - MarketBeat at news.google.com
27th of January 2025
Disposition of 25000 shares by Douglas Treco of Inozyme Pharma subject to Rule 16b-3 at MacroaxisInsider
21st of January 2025
Disposition of 3219 shares by Siemers Eric of Acumen Pharmaceuticals at 1.59 subject to Ru... at MacroaxisInsider
17th of January 2025
Nasdaq Surges Over 300 Points State Street Earnings Top Views at benzinga.com
16th of January 2025
Acquisition by Myron Holubiak of 200000 shares of Citius Pharmaceuticals at 1.01 subject t... at Myron Holubiak
10th of January 2025
HOOKIPA Pharma explores acquisition of Poolbeg Pharma at investing.com
10th of January 2025
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children w... at finance.yahoo.com
8th of January 2025
Citius Pharmaceuticals falls as it looks to raise 3M in direct offering at seekingalpha.com
7th of January 2025
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference at gurufocus.com
2nd of January 2025
Citius Pharmaceuticals Upgraded at D. Boral Capital at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Citius Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Citius Pharmaceuticals' short interest history, or implied volatility extrapolated from Citius Pharmaceuticals options trading.
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.